Systemic Lupus Erythematosus (SLE)


Epidemiology


Etiology

Drug-induced SLE

(Note: estrogen-containing oral contraceptives and ibuprofen are known to exacerbate SLE, but are probably not etiologies of drug-induced SLE)


Physiology


Diagnosis

CBC

Serology

ANA

Anti-Phospholipid Antibodies

Other Autoantibodies

Protein C and S

Serum Complement

ESR

Bone X-Rays

Brain MRI

Arthrocentesis

Renal Bx

Skin Bx


Clinical Criteria: 1982 American College of Rheumatology

(need at least 4)


Clinical Presentations

Pulmonary Manifestations

(occur in 38-89% of SLE cases)

Interstitial Lung Disease (Chronic Interstitial Lupus Pneumonitis) (see [[ILD-Etiology]])

Acute Lupus Pneumonitis (see [[Pneumonia]])

Pleuritis (see [[Pleural Effusion-Exudate]])

Shrinking/Vanishing Lung Syndrome

Pulmonary Hypertension (see Pulmonary Hypertension, [[Pulmonary Hypertension]])

Acute PE

Anti-Phospholipid Antibody Syndrome (see [[Anti-Phospholipid Antibody Syndrome]])

Diffuse Alveolar Hemorrhage (see [[Diffuse Alveolar Hemorrhage]])

Cricoarytenoid Arthritis (see [[Cricoarytenoid Arthritis]])

Epiglottitis/Laryngitis/Vocal Cord Edema (see [[Epiglottitis]])

Bronchiolitis Obliterans (see [[Bronchiolitis Obliterans]])

Cryptogenic Organizing Pneumonia (see [[Cryptogenic Organizing Pneumonia]])

Lymphocytic Interstitial Pneumonia (see [[Lymphocytic Interstitial Pneumonia]])

Acute Reversible Hypoxemia

Pulmonary Infection

Atelectasis (see [[Atelectasis]])

Necrotizing Tracheitis


Rheumatologic Manifestations

Dermatologic Involvement

Renal Manifestations

Cardiac Manifestations

GI Manifestations

Neurologic Manifestations

Heme Manifestations

Ocular Manifestations

Other Manifestations


Clinical Manifestations of Drug-induced SLE


Treatment

Treatment of Diffuse Alveolar Hemorrhage

Treatment of Pulmonary Hypertension

Parameters to Follow with Therapy

Treatment of Drug-Induced SLE

Treatment of Co-Existing Cardiac Disease


Prognosis


References